Summary & Overview
CPT 81353: TP53 Familial Variant Analysis, Technical Component
CPT code 81353 represents the technical component of a targeted molecular diagnostic assay that analyzes known familial variants in the TP53 gene to evaluate relatives for germline mutations tied to Li–Fraumeni syndrome. Nationally, targeted hereditary cancer testing such as this is important for cascade testing, risk stratification, and informing clinical surveillance strategies for high-penetrance cancer syndromes. The code specifies the laboratory’s technical work in processing and generating test data from patient specimens.
Key payers in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for TP53 familial variant testing, typical sites of service, and the service type. The publication summarizes payer coverage considerations and common modifier usage associated with laboratory services where available. It also outlines benchmarks and policy topics relevant to hereditary molecular testing, including coding distinctions between technical and professional components, implications for cascade testing workflows, and billing practice notes. Data not provided in the input (such as specific coverage policies by payer, associated taxonomies, ICD-10 diagnoses, related codes, and service-line identifiers) are noted as unavailable where applicable.
Billing Code Overview
CPT code 81353 describes the technical laboratory assay performed on a patient specimen (for example, blood) to analyze known familial variants in the tumor protein 53 (TP53) gene. The test evaluates family members for germline TP53 mutations associated with hereditary Li–Fraumeni syndrome.
Service type: Molecular diagnostic testing — targeted germline variant analysis
Typical site of service: Clinical molecular laboratory or hospital laboratory (specimen collected in an outpatient or ambulatory setting and processed in a laboratory)
Clinical & Coding Specifications
Clinical Context
A patient with a family history of early-onset cancers is referred for targeted germline testing of the TP53 gene. Typical patients include adult relatives of an index case already found to carry a pathogenic TP53 variant, or an individual with a strong personal/family history suggestive of Li–Fraumeni syndrome who requires confirmatory familial variant testing. The clinical workflow begins with genetic counseling and informed consent, sample collection (usually peripheral blood in an EDTA tube or occasionally saliva), specimen labeling and transport to a molecular diagnostics laboratory, and receipt of the test order specifying the known familial TP53 variant. In the laboratory, a molecular technologist performs the targeted assay (e.g., PCR-based sequencing, allele-specific PCR, or targeted genotyping) to determine presence or absence of the familial variant. Results are reviewed by a laboratory director or clinical geneticist and reported to the ordering provider and genetic counselor for disclosure to the patient. Typical site of service is an outpatient genetics clinic, physician office, or a reference molecular diagnostics laboratory. Common clinical scenarios include cascade testing of adult family members, prenatal consultation when a parent is known to carry a TP53 pathogenic variant, or pre-test confirmation for patients with tumor profiles suggestive of germline TP53 alterations.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Procedure fully furnished by billing entity (default) | Use when no specific modifier applies and standard billing applies |